Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that several advertising campaigns incorrectly compare the effectiveness of its obesity and diabetes treatments, a new episode in the competition between the two pharmaceutical companies for market leadership in GLP-1 drugs.
Furthermore, the Danish company filed a lawsuit in a federal court in New Jersey, arguing that Eli Lilly used clinical trials with doses that no longer represent the most recent versions of the marketed treatments. According to Novo Nordisk, this comparison could create a misleading perception of the performance of Wegovy and Ozempic compared to Zepbound and Mounjaro.
Novo Nordisk questions advertising comparisons
The company argues that the advertisements released by Eli Lilly rely on results obtained with earlier versions of Wegovy and Ozempic while omitting the fact that the FDA approved a higher dose of Wegovy this year. From Novo Nordisk’s perspective, this information alters the clinical context used to compare weight loss achieved with the different medications.
Likewise, the pharmaceutical company requests that the company withdraw the campaigns in question and publish corrective advertising to clarify the information presented to patients and health professionals.
Eli Lilly defends scientific evidence
For its part, Eli Lilly rejected the accusations and stated that its advertisements reflect the results of the SURMOUNT-5 study, a clinical investigation used to compare the effectiveness of its treatments with the doses available when the trial was developed.
The company maintained that it will continue to defend the scientific validity of its campaigns and will respond to the lawsuit during the legal process.
An increasingly competitive market
The litigation reflects the intense competition between Novo Nordisk and Eli Lilly for leadership of the U.S. market for obesity drugs, one of the fastest-growing segments within the pharmaceutical industry.
Over the past few years, both companies have increased their investments in GLP-1 receptor agonist-based treatments while developing new formulations to improve weight loss and diabetes management. This situation has intensified market competition and scrutiny of the advertising used to promote these medications.
Possible implications
If the court rules in favor of Novo Nordisk, Eli Lilly could be forced to modify or withdraw some of its advertising campaigns, in addition to facing potential financial compensation. Meanwhile, the case adds a new legal front to the rivalry between two of the largest companies in the global obesity treatment market.
Source: Reuters
Photo: Shutterstock
